Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotect for Preventive Treatment of CMV Infection in Renal Transplantation
NCT04934527Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- IgG Antibodies, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human cytomegalovirus immune globulin in cytomegalovirus infection (CMV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Occurrence of CMV infection at 12 months. Started Nov 2021; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04934527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934527.